Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034827 | A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer | PHASE2 | COMPLETED | 172 | — | — | Jan 1, 2002 | May 1, 2003 | May 4, 2007 | 30 | United States |
| Name | Type | Description |
|---|---|---|
| CI-1040 | DRUG | - |
Inclusion Criteria: * Patients who are at least 18 years or older who have pathological or hiostological confirmation of colorectal, nonsmall cell lung cancer, breast, or pancreas cancer. * No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast no prior chemotherapy for panc...